Phase 1/1b study of telisotuzumab vedotin (Teliso-V) plus osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Goldman, Jonathan W.
Horinouchi, Hidehito
Cho, Byoung Chul
Tomasini, Pascale
Dunbar, Martin
Hoffman, David
Parikh, Apurvasena
Blot, Vincent
Camidge, D. Ross
机构：
[1] UCLA, David Geffen Sch Med, Los Angeles, CA USA
[2] Natl Canc Ctr, Tokyo, Japan
[3] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[4] Aix Marseille Univ, Hop Nord, APHM, INSERM,CNRS,CRCM,Multidisciplinary Oncol & Therap, Marseille, France
[5] AbbVie Inc, N Chicago, IL USA
[6] AbbVie Inc, South San Francisco, CA USA
[7] Univ Colorado, Canc Ctr, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9013
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase 1b Study of Demcizumab Plus Pemetrexed and Carboplatin in Patients with 1st Line Non-Small Cell Lung Cancer (NSCLC)
    McKeage, M.
    Kotasek, D.
    Millward, M.
    Markman, B.
    Jameson, M.
    Hidalgo, M.
    Harris, D.
    Stagg, R.
    Dupont, J.
    Hughes, B.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 183 - 184
  • [42] Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
    Eide, Inger Johanne Zwicky
    Helland, Aslaug
    Ekman, Simon
    Mellemgaard, Anders
    Hansen, Karin Holmskov
    Cicenas, Saulius
    Koivunen, Jussi
    Gronberg, Bjorn Henning
    Brustugun, Odd Terje
    LUNG CANCER, 2020, 143 : 27 - 35
  • [43] Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis
    Lu, S.
    Cho, B. C.
    Lee, J-S.
    Lee, S-H.
    Danchaivijitr, P.
    Liu, B.
    Alip, A.
    Xiong, H.
    How, S. H.
    Chang, G-C.
    Yang, J. C-H.
    Yoshioka, H.
    Xia, K.
    Martinez, M.
    Bauml, J. M.
    Sethi, S.
    Hayashi, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1661 - S1661
  • [44] Phase 1b study of capecitabine and erlotinib in advanced non-small cell lung cancer
    Lu, S.
    Popat, S.
    Puglisi, M.
    Kaudeer, N.
    Gennatas, S.
    Hewish, M.
    Ayite, B.
    Bhosle, J.
    O'Brien, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S828 - S828
  • [45] Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)
    Yang, James Chih-Hsin
    Ohe, Yuichiro
    Chiu, Chao -Hua
    Ou, Xiaoling
    Cantarini, Mireille
    Janne, Pasi A.
    Hartmaier, Ryan J.
    Ahn, Myung Ju
    CLINICAL CANCER RESEARCH, 2022, 28 (19) : 4222 - 4231
  • [46] A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Pillai, R.
    Ramalingam, S.
    Paz-Ares, L.
    Thayu, M.
    Watson, P.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2288 - S2288
  • [47] First-in-human study of ABBV-637, an EGFR-targeting BCL-XL-inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)
    Rotow, J. K.
    Waqar, S. N.
    Papadopoulos, K. P.
    Hung, J-Y.
    Spira, A. I.
    Gan, H.
    Yoshida, T.
    Kuo, C-H. S.
    Doger de Speville, B.
    Felip, E.
    Yoh, K.
    Morrison-Thiele, G.
    Robinson, R.
    Rudraganguly, N.
    Saab, R.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [48] A Phase 1b Study of the MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination with Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer
    Steuer, C.
    Carlisle, J.
    Leal, T.
    Ardeshir, F.
    Holmes, M.
    Schneider, F.
    Chen, Z.
    Switchenko, J.
    Ross, J.
    Selvagi, G.
    Owonikoko, T.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S196 - S196
  • [49] A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
    Jin-Ji Yang
    Jian Fang
    Yong-Qian Shu
    Jian-Hua Chang
    Gong-Yan Chen
    Jian Xing He
    Wei Li
    Xiao-Qing Liu
    Nong Yang
    Caicun Zhou
    Jian An Huang
    Melanie M. Frigault
    Ryan Hartmaier
    Ghada F. Ahmed
    Coumaran Egile
    Shethah Morgan
    Remy B. Verheijen
    Anders Mellemgaard
    Liu Yang
    Yi-Long Wu
    Investigational New Drugs, 2021, 39 : 477 - 487
  • [50] Osimertinib in Relapsed EGFR-Mutated, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) Patients: Results from the TREM-Study
    Eide, I. J.
    Helland, A.
    Borrisova, S.
    Ekman, S.
    Cicenas, S.
    Koivunen, J.
    Gronberg, B. H.
    Brustugun, O. T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2140 - S2141
12345